KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Long-Term Investments (2017 - 2022)

Guardant Health's Long-Term Investments history spans 6 years, with the latest figure at $156.7 million for Q3 2022.

  • On a quarterly basis, Long-Term Investments fell 37.36% to $156.7 million in Q3 2022 year-over-year; TTM through Sep 2022 was $156.7 million, a 37.36% decrease, with the full-year FY2021 number at $698.0 million, up 183.07% from a year prior.
  • Long-Term Investments hit $156.7 million in Q3 2022 for Guardant Health, down from $382.6 million in the prior quarter.
  • Over the last five years, Long-Term Investments for GH hit a ceiling of $698.0 million in Q4 2021 and a floor of $3.0 million in Q3 2018.
  • Historically, Long-Term Investments has averaged $235.6 million across 5 years, with a median of $242.4 million in 2020.
  • Biggest five-year swings in Long-Term Investments: soared 10113.43% in 2019 and later tumbled 83.02% in 2020.
  • Tracing GH's Long-Term Investments over 5 years: stood at $77.6 million in 2018, then skyrocketed by 246.54% to $268.8 million in 2019, then dropped by 8.25% to $246.6 million in 2020, then surged by 183.07% to $698.0 million in 2021, then tumbled by 77.55% to $156.7 million in 2022.
  • Business Quant data shows Long-Term Investments for GH at $156.7 million in Q3 2022, $382.6 million in Q2 2022, and $588.5 million in Q1 2022.